Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "Emergency"

390 News Found

Aurobindo Pharma rolls out Molnaflu in India
News | January 06, 2022

Aurobindo Pharma rolls out Molnaflu in India

The brand is now available pan-India through their distribution partner


ENTOD Pharmaceuticals set to launch Molentod
News | January 06, 2022

ENTOD Pharmaceuticals set to launch Molentod

It is the generic version of molnupiravir


Dr Reddy’s molnupiravir priced at Rs 1,400 for a course
News | January 04, 2022

Dr Reddy’s molnupiravir priced at Rs 1,400 for a course

Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.


Novavax submits data to U.S. FDA for Covid-19 EUA
Biotech | January 03, 2022

Novavax submits data to U.S. FDA for Covid-19 EUA

Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance


U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
News | January 03, 2022

U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older

First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age


Emcure to launch oral Covid-19 drug soon
Drug Approval | January 03, 2022

Emcure to launch oral Covid-19 drug soon

A toll-free helpline to be set up to help doctors and patients


Biological E gets nod to study Corbevax as a booster dose
News | December 30, 2021

Biological E gets nod to study Corbevax as a booster dose

The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions


Siemens Healthineers receive EUA for Covid-19 antigen self-test
Medical Device | December 30, 2021

Siemens Healthineers receive EUA for Covid-19 antigen self-test

Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure


Study demonstrates Covaxin safe for kids in the age 2-18 years
News | December 30, 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults


JB Chemicals and Pharmaceuticals to launch molnupiravir next month
Drug Approval | December 29, 2021

JB Chemicals and Pharmaceuticals to launch molnupiravir next month

It will be marketed under the brand name Molunamax